First Week of LIVN July 17th Options Trading

LivaNova PLC (LIVN) is being highlighted for two option strategies around the current share price of $66.97: a sell-to-open $62.50 put (bid $3.90) which nets an effective cost basis of $58.60 and is ~7% out-of-the-money with a 65% chance to expire worthless, implying a 6.24% return (13.81% annualized) if it does; and a covered-call using the $70.00 strike (bid $5.50) that would deliver a 12.74% total return to July 17 if called and is ~5% out-of-the-money with a 49% chance to expire worthless, giving an 8.21% yield boost (18.17% annualized). Implied volatility on both contracts is roughly 46% (trailing 12-month volatility ~45%); StockOptionsChannel will track odds and contract histories on its site.

Analysis

Market structure: The current LIVN option setup favors income-focused retail/CTA sellers and market makers collecting premium; cash‑secured put sellers win if shares are assigned at an effective basis of $58.60 (−12.5% vs $66.97), while upside-focused longs lose optionality if covered calls cap gains above $70. Options liquidity and IV (≈46%) roughly in line with realized vol (45%) signal balanced supply/demand for hedging, not a panic-induced premium. Cross-asset impact is negligible outside healthcare equity flows; a heavyweight idiosyncratic shock could force funding flows into high‑yield credit and depress small-cap biotech baskets.

Risk assessment: Tail risks are regulatory device recalls, adverse FDA rulings, or reimbursement shocks that could tank LIVN >30% in days, making short-put income strategies painful. In the immediate term (days) options decay favors sellers; short-term (weeks) earnings/FDA windows can flip implied vol [phone] bps; long-term (quarters) fundamentals (procedure volumes, M&A) determine recovery. Hidden dependencies include elective procedure cycles and hospital capex — a macro slowdown amplified downside. Catalysts to watch in 30–90 days: quarterly results, any FDA/recall notices, and M&A rumors.

Trade implications: Tactical direct plays: small, structured income trades rather than naked directional bets. Prefer cash‑secured puts at 62.50 (collect $3.90) sized to 1–3% portfolio exposure with strict assignment rules, or buy‑write (buy at ~$67, sell Jul‑70 for $5.50) to harvest ~12.7% to expiration while capping upside. Avoid large naked short‑vol positions; IV≈realized removes a persistent edge for premium sellers. Use collars or vertical put spreads to limit tail losses if assigned (e.g., buy 55 put, sell 60 put).

Contrarian angle: The market treats these as passive yield trades but underprices binary regulatory risk; the premium (6–8% yield to expiration) compensates little for a one‑quarter 30% downside risk. If you expect M&A or positive trial/FDA news inside 60–120 days, covered calls materially underprice upside — a small LEAP call or uncapped long position can outperform. Conversely, if you fear a binary adverse event, selling the put is underdone risk: buy protective puts or use smaller sizes.

Key Decisions for Investors

• Sell cash‑secured LIVN Jul 17 62.50 puts (collect $3.90) sized to represent no more than 1–3% of portfolio exposure (number of contracts = floor(0.02 * AUM / $6,250)). Close/roll if LIVN > $70 or cut losses and buy protection if LIVN trades down >12% from entry.
• Establish a buy‑write: purchase LIVN at market (~$66.97) up to 1–2% portfolio and sell Jul 17 70 calls for $5.50 to lock ~12.7% return to expiry; if called, accept assignment; if IV falls <40% and stock rallies, roll calls up 1–2 strikes.
• If assigned or long stock and worried about a regulatory tail, implement a protective collar: buy Jul 17 55 puts and finance by selling Jul 17 60 puts (or reduce by selling shorter dated calls) to limit downside to ~10–15% at capped cost.
• Avoid aggressive long or short directional positions in LIVN funded by short vol; instead wait for a vol dislocation >200–300bps (IV>48–50% vs realized) or a clear catalyst (FDA/earnings) within 30–90 days before scaling beyond income-sized positions.